Anika Therapeutics, Inc. (NASDAQ:ANIK) Stock Holdings Lowered by Point72 Asia Singapore Pte. Ltd.

Point72 Asia Singapore Pte. Ltd. cut its position in Anika Therapeutics, Inc. (NASDAQ:ANIK) by 68.4% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,922 shares of the biotechnology company’s stock after selling 6,323 shares during the quarter. Point72 Asia Singapore Pte. Ltd.’s holdings in Anika Therapeutics were worth $72,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Stonepine Capital Management LLC increased its stake in shares of Anika Therapeutics by 171.4% in the second quarter. Stonepine Capital Management LLC now owns 165,397 shares of the biotechnology company’s stock valued at $4,190,000 after purchasing an additional 104,448 shares during the period. Riverwater Partners LLC grew its holdings in Anika Therapeutics by 539.1% in the 3rd quarter. Riverwater Partners LLC now owns 101,996 shares of the biotechnology company’s stock worth $2,552,000 after buying an additional 86,037 shares in the last quarter. Meros Investment Management LP grew its holdings in Anika Therapeutics by 25.0% in the 2nd quarter. Meros Investment Management LP now owns 212,714 shares of the biotechnology company’s stock worth $5,388,000 after buying an additional 42,587 shares in the last quarter. Renaissance Technologies LLC increased its position in Anika Therapeutics by 6.9% in the 2nd quarter. Renaissance Technologies LLC now owns 598,229 shares of the biotechnology company’s stock valued at $15,153,000 after acquiring an additional 38,412 shares during the period. Finally, Acadian Asset Management LLC raised its stake in Anika Therapeutics by 5.1% during the 2nd quarter. Acadian Asset Management LLC now owns 442,944 shares of the biotechnology company’s stock valued at $11,217,000 after acquiring an additional 21,517 shares in the last quarter. 91.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on ANIK shares. StockNews.com cut Anika Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, November 4th. Barrington Research lowered their target price on shares of Anika Therapeutics from $37.00 to $25.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st.

Anika Therapeutics Stock Performance

Shares of NASDAQ ANIK opened at $17.45 on Friday. Anika Therapeutics, Inc. has a 1 year low of $16.00 and a 1 year high of $29.11. The firm has a market cap of $255.57 million, a P/E ratio of -2.62 and a beta of 0.89. The stock has a fifty day moving average price of $20.74 and a two-hundred day moving average price of $24.09.

About Anika Therapeutics

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.